MADISON, Wis., Sept. 14, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company will host a discussion with analysts and investors on Tuesday, October 3, 2023, in conjunction with the American Society of Radiation Oncology (ASTRO) Annual Meeting. The event will take place in person at the ASTRO meeting and on a virtual platform, with presentations beginning at 1:30 pm PT (4:30 pm ET).
The Investor Day will feature the Accuray leadership team who will highlight the company's vision for advancing patient care while creating value for stakeholders. Global thought leaders will share their perspectives on Accuray technology and the future of radiation medicine. Both in-person and virtual attendees must register in advance to participate. Please RSVP here by September 27, 2023. A replay of the meeting will be available on the company's website following the event.
About Accuray
Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions that are designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Madison, Wisconsin, with facilities worldwide. To learn more, visit www.accuray.com or follow us on Facebook, LinkedIn, Twitter, and YouTube.
Investor Contact
Aman Patel, CFA
Investor Relations, ICR-Westwicke
+1 (443) 450-4191
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact
Beth Kaplan
Accuray
+1 (408) 789-4426
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$2.15 |
Daily Change: | 0.06 2.87 |
Daily Volume: | 770,303 |
Market Cap: | US$213.370M |
November 06, 2024 September 10, 2024 August 27, 2024 August 14, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORERecursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB